Misonix Incorporated; American Burn Association (“ABA”) 2015 National Conference

FARMINGDALE, N.Y., April 23, 2015 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced the presentation of additional data on the Misonix SonicOne O.R. surgical instrument at the American Burn Association (“ABA”) 2015 National Conference in Chicago, held April 21-24, 2015. The ABA and its more than 3,500 members promote and support burn-related research, education, care, rehabilitation, and prevention.

The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. has received a favorable response from burn surgeons because of its ability to cost effectively apply ultrasonic debridement to a variety of burn wounds in preparation for skin grafts.

The expanded data set was presented by Abraham Houng, MD, Associate Program Director for the Division of Burn Surgery at Saint Barnabas Medical Center in Livingston, New Jersey (the 5th largest burn center in the United States) as a follow up to an initial series reported on last year. The data indicates ultrasound debridement reduces the potential for sharps injury thus delivering a potential safer application for both the patient and hospital staff. The data also confirms previously reported findings that blood loss in the ultrasound debridement group of the study was on average 42% less than in the standard debridement group (0.54 ml/cm² for the ultrasonic debridement group compared to 0.91 ml/cm² for the standard debridement group).

Dr. Houng shared his experience with the SonicOne O.R. during the ABA in the Misonix Hands On Lab. “The SonicOne O.R. is establishing a clinical record of safety and effectiveness as an important advancement in helping us treat a very sick patient population.” The data report and the Hands On Lab allowed visiting burn surgeons and their staffs to trial the device for themselves to see the benefits in action.

The ABA also marked the unveiling of a case series report entitled “Using low-frequency contact ultrasound for debridement in the burn population” by Ariel Aballay M.D., FACS, Medical Director West Penn Hospital Burn Center. The case series reports the importance of tissue selectivity seen in ultrasonic debridement when treating burn patients.

Dr. Aballay shared his experience with the SonicOne O.R. during the ABA in the Misonix Hands On Lab. “The SonicOne O.R. could help answer the question of whether a deep second degree burn will require skin grafts or can heal on its own, potentially reducing healing time and patient length of stay. We look forward to continued research to answer these important questions.”

“We remain enthusiastic as we continue to see more facilities electing to bring SonicOne O.R. into their operating rooms,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “This additional data presented at the ABA meeting further validates the clinical benefits of our unique technology.”

About Misonix, Inc.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/additional-data-confirms-reduction-in-blood-loss-with-misonix-sonicone-or-in-burn-patients-at-2015-national-american-burn-association-meeting-300071165.html

SOURCE Misonix, Inc.